Delivery Order SPE2DB24D1201-SPE2DB25FJDVY
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $4,917.74 to AmerisourceBergen Drug Corp for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens. This competitively awarded, firm fixed-price delivery order was issued on July 31, 2025, with an ultimate completion date of August 1, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The contract represents a small-value transaction within AmerisourceBergen's broader federal...
- The Defense Logistics Agency awarded a delivery order valued at $1,779.30 to AmerisourceBergen Drug Corp for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens. This competitive award, issued on August 7, 2025, with an ultimate completion date of August 8, 2025, represents a firm fixed-price transaction with no set-aside designation. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, reflecting the company's role as a major...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, valued at $1,443.47. This firm fixed-price delivery order was competitively awarded without a set-aside designation and is scheduled for completion by August 8, 2025. The product will be supplied to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is issued under...
- The Defense Logistics Agency awarded a $4,479.33 firm fixed-price delivery order to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with an ultimate completion date of August 20, 2025. This non-set-aside contract was competitively awarded and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order represents a single transaction within AmerisourceBergen's broader pharmaceutical supply relationship with the federal government....
- The Defense Logistics Agency (DLA) awarded a $1,089.56 firm fixed price delivery order to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens. The contract, which is a child order under a larger vehicle, was competitively awarded without a set-aside designation and carries an ultimate completion date of September 5, 2025. Performance will take place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with a ceiling value of $2,108.70. This competitively awarded, non-set-aside contract represents a firm fixed price delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through December 2026. The place of performance is...
- The Defense Logistics Agency awarded a delivery order valued at $2,273.88 to AmerisourceBergen Drug Corp for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with an ultimate completion date of September 2, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The contract represents a continuation of AmerisourceBergen's ongoing pharmaceutical...
- The Defense Logistics Agency Medical Supply Chain awarded AmerisourceBergen Drug Corp a delivery order valued at $5,751.48 for NovoLog 100 Unit/mL FlexPen 3mL insulin pens on July 25, 2025, with an ultimate completion date of July 28, 2025. This firm fixed-price delivery order represents a competitive, non-set-aside award to supply pharmaceutical products supporting federal military and veteran healthcare systems. The work will be performed at AmerisourceBergen's corporate office in...
- The Defense Logistics Agency awarded a delivery order valued at $3,874.48 to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with an ultimate completion date of September 3, 2025. This non-set-aside, firm fixed price delivery order was competitively awarded and represents a routine pharmaceutical supply transaction under the company's existing contract vehicle. The place of performance is AmerisourceBergen's corporate office located in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $2,537.84 firm fixed price delivery order on July 29, 2025, for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with an ultimate completion date of July 30, 2025. This non-competitive delivery order was placed against AmerisourceBergen's existing indefinite delivery contract (IDC) with DLA Troop Support Medical, designated SPE2DX, valued at $999,999,999.00 and running through December 2026. The product will be delivered to the...
- SPE2DB24D1201Indefinite Delivery Contract
- SPE2DB24D1201-SPE2DB25FJDVYDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,746.24 to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens. This non-set-aside contract was executed on August 11, 2025, with an ultimate completion date of August 12, 2025, and represents a firm fixed price delivery order for pharmaceutical supplies. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order operates under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle extending through December 2026. As a prime vendor for the Defense Logistics Agency's medical supply chain, AmerisourceBergen provides comprehensive pharmaceutical and medical supply support to military healthcare systems and other federal agencies, including the Defense Health Agency and U.S. Coast Guard. The company's extensive portfolio spans specialty medications, vaccines, generic and brand-name drugs, and medical devices across multiple therapeutic domains, supporting military personnel and veteran healthcare needs worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.7k | 8/11/25 |